



DBV Technologies expands its Board of Directors

19 February 2009, Paris, France – DBV Technologies (DBV), a biopharmaceutical company specialising in the development of non-invasive epicutaneous diagnostics and immunotherapies for allergies, announced today that it has expanded its Board of Directors with the appointment of Peter Barton Hutt as Non-Executive Director.

Hutt brings extensive knowledge and first-hand experience of US food and drug legislation to DBV. He is currently a senior counsel in the Washington DC law firm of Covington & Burling LLP, specialising in Food and Drug Law, and teaching a full course on Food and Drug Law at Harvard Law School each year. He has been a member of the US Institute of Medicine since its establishment in 1971 and was formerly Chief Counsel for the US Food and Drug Administration.

This board appointment is of strategic importance as DBV works towards a Phase I study for peanut allergy desensitization in the US. Commenting on Mr. Hutt's appointment, Jean François Biry, Chairman and CEO of DBV, said, "We are delighted that we have been able to attract such a high calibre member to our board who will be integral in supporting DBV Technologies' visibility in the US."